Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
26 Certain GLP-1 agonist drugs have been associated with a significantly increased risk of depression and anxiety, 27 highlighting an emerging need for complimentary therapies to support patients mental and emotional health while undergoing pharmaceutical GLP-1 therapy
Notable exclusions include antibodies, label expansion, biosimilars
Early trial results In phase 2 trials, Retatrutide delivered impressive results: Mean weight reduction of up to ~17.5% at 24 weeks, rising to ~24.2% at 48 weeks in overweight/obese adults
Methods This was a substudy of a randomised clinical trial on the effects of semaglutide and empagliflozin alone or in combination
Gilkerson RW, De Vries RL, Lebot P, Wikstrom JD, Torgyekes E, Shirihai OS, et al
It's filling
US$ 23.65
US$ 27.01
US$ 28.00
US$ 29.52
US$ 26.20
